NCT05094804: A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With a PD-1 Inhibitor

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: TNBC patients must have received one line of chemotherapy and a PARP inhibitor (if eligible based on BRCA mutation status) in the metastatic setting
Exclusions: Patients with active, symptomatic central nervous system (CNS) metastases or leptomeningeal disease – see trial for details

Comments are closed.

Up ↑